Vaccinex, Inc. (VCNX)
OTCMKTS
· Delayed Price · Currency is USD
0.910
+0.010 (1.11%)
Apr 28, 2026, 9:30 AM EST
Vaccinex Employees
As of December 31, 2024, Vaccinex had 27 total employees, including 23 full-time and 4 part-time employees. The number of employees decreased by 13 or -32.50% compared to the previous year.
Employees
27
Change (1Y)
-13
Growth (1Y)
-32.50%
Revenue / Employee
$24,040
Profits / Employee
-$745,360
Market Cap
2.44M
Employees Chart
Vaccinex News
- 1 year ago - Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting - GlobeNewsWire
- 1 year ago - Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) - GlobeNewsWire
- 1 year ago - Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - GlobeNewsWire
- 1 year ago - Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 year ago - Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC - GlobeNewsWire
- 1 year ago - Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting - GlobeNewsWire
- 1 year ago - Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain - GlobeNewsWire
- 1 year ago - Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds - GlobeNewsWire